Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

Trial Profile

Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms ZOSTER-026
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Nov 2017 Results assessing immunogenecity,reactogenecity and safety published in the Vaccine.
    • 10 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Jul 2014 Planned primary completion date changed from 1 Jun 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top